Plain-English translation of NCT06706973 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying the genetic 'fingerprints' — called epigenetic marks — in head and neck cancer tissue to learn more about how this disease develops and behaves. By analyzing tissue samples from patients with newly diagnosed head and neck cancer, they hope to find better ways to diagnose the disease and create more effective treatments tailored to each patient's specific cancer.
Head and neck cancer is complex and varies widely from person to person, depending on factors like smoking, alcohol use, or HPV infection. This study exists to uncover the genetic differences that drive these cancers, so doctors can eventually offer more personalized diagnosis and treatment approaches.
You likely qualify if…
You likely don't qualify if…
As a participant, you would allow researchers to obtain and analyze tissue samples from your cancer — either samples already collected for your diagnosis or new samples if needed. The study does not require you to take any medication or undergo additional invasive procedures beyond what is already necessary for your treatment and care. Your role is to contribute biological material and information that helps researchers better understand head and neck cancer.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Italy
Sponsor
European Institute of Oncology
Collaborators
Associazione Italiana per la Ricerca sul Cancro
Enrollment target
~60 participants
Started
March 2024
Primary completion
April 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Susanna Chiocca, Doctor
Istituto Europeo di Oncologia
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.